-
Pharmaids Pharmaceuticals Announces Positive Phase II Results for PPL-101 in Metastatic Colorectal Cancer
Pharmaids Pharmaceuticals Ltd. (Nasdaq: PHAR) today announced positive top-line results from its Phase II clinical trial evaluating PPL-101 in patients with metastatic colorectal cancer (mCRC) who have progressed on or after standard first-line therapy.
-
Pharmaids Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
Pharmaids Pharmaceuticals Ltd. (Nasdaq: PHAR) today announced that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 4:00 PM ET / 1:00 PM PT in San Francisco, CA.
-
Pharmaids Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Pharmaids Pharmaceuticals Ltd. (Nasdaq: PHAR) today announced the pricing of its previously announced underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $12.50 per share.
-
Pharmaids Pharmaceuticals Announces Positive Phase IIa Results for PHA102 in Glaucoma
Pharmaids Pharmaceuticals Ltd. (AIM: PDS), a specialty pharmaceutical company focused on the elderly patient population, today announced positive top-line results from its Phase IIa clinical trial evaluating PHA102, its novel, proprietary, topical formulation of acetazolamide, for the treatment of glaucoma.
-
Pharmaids Pharmaceuticals Provides Trading Update for the Year Ended 31 December 2022
Pharmaids Pharmaceuticals Ltd. (AIM: PDS), a specialty pharmaceutical company focused on the elderly patient population, today provided a trading update for the year ended 31 December 2022.
-
Pharmaids Pharmaceuticals Announces Positive Phase II Results for PHA102 in Idiopathic Pulmonary Fibrosis
Pharmaids Pharmaceuticals Ltd. (AIM: PDS), a specialty pharmaceutical company focused on the elderly patient population, today announced positive top-line results from its Phase II clinical trial evaluating PHA102, its novel, proprietary, topical formulation of acetazolamide, for the treatment of idiopathic pulmonary fibrosis (IPF).
-
Pharmaids Pharmaceuticals Ltd. Announces Positive Results from Phase 2 Clinical Trial of PLX-123
Pharmaids Pharmaceuticals Ltd. (NASDAQ: PHAID) today announced positive results from a Phase 2 clinical trial of its lead product candidate, PLX-123, in patients with moderate-to-severe plaque psoriasis.
-
Pharmaids Pharmaceuticals Ltd. Appoints New Chief Medical Officer
Pharmaids Pharmaceuticals Ltd. (NASDAQ: PHAID) today announced the appointment of Dr. John Smith as its new Chief Medical Officer.
-
Pharmaids Pharmaceuticals Ltd. Announces Collaboration with Leading Dermatology Center
Pharmaids Pharmaceuticals Ltd. (NASDAQ: PHAID) today announced a collaboration with the University of California, San Francisco (UCSF) Department of Dermatology.
-
Pharmaids Pharmaceuticals Ltd. Announces New Collaboration with Leading Healthcare Provider
Pharmaids Pharmaceuticals Ltd. (PL), a leading global pharmaceutical company, today announced a new collaboration with XYZ Healthcare, a leading healthcare provider in the region. The collaboration will focus on developing and commercializing innovative new therapies for patients with unmet medical needs.
-
Pharmaids Pharmaceuticals Ltd. Reports Strong Financial Results for 2022
Pharmaids Pharmaceuticals Ltd. (PL) today reported strong financial results for the year ended December 31, 2022. The company's revenue increased by 15% to $10 billion, while net income increased by 20% to $2 billion. The company attributed its strong performance to the successful launch of several new products, as well as the continued growth of its core business.
-
Pharmaids Pharmaceuticals Ltd. Appoints New CEO
Pharmaids Pharmaceuticals Ltd. (PL) today announced the appointment of Dr. John Smith as its new Chief Executive Officer (CEO). Dr. Smith has over 20 years of experience in the pharmaceutical industry, most recently serving as the CEO of ABC Pharmaceuticals. He is a recognized leader in the industry and has a proven track record of success in developing and commercializing innovative new therapies.
-
Pharmaids Pharmaceuticals Ltd. Announces Positive Phase 3 Results for New Alzheimer's Drug
Pharmaids Pharmaceuticals Ltd. today announced positive Phase 3 results for its new Alzheimer's drug, PA-101. The results showed that PA-101 significantly improved cognitive function and reduced disease progression in patients with mild to moderate Alzheimer's disease.
-
Pharmaids Pharmaceuticals Ltd. to Acquire BioTech Company for $1.5 Billion
Pharmaids Pharmaceuticals Ltd. announced today that it has entered into an agreement to acquire BioTech Company for $1.5 billion. The acquisition will give Pharmaids Pharmaceuticals Ltd. access to BioTech Company's novel drug discovery platform, which has the potential to accelerate the development of new treatments for a variety of diseases.
-
Pharmaids Pharmaceuticals Ltd. Receives FDA Approval for New Diabetes Drug
Pharmaids Pharmaceuticals Ltd. today announced that it has received FDA approval for its new diabetes drug, PA-201. PA-201 is a once-daily oral medication that is indicated for the treatment of type 2 diabetes.
-
Pharmaids Pharmaceuticals Announces Positive Results from Phase 2 Trial of PA-101 for the Treatment of Acute Myeloid Leukemia
Pharmaids Pharmaceuticals Ltd. (Nasdaq: PAHC), a clinical-stage biopharmaceutical company developing novel targeted therapies for the treatment of cancer, today announced positive results from its Phase 2 clinical trial of PA-101 for the treatment of Acute Myeloid Leukemia (AML). The trial met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients treated with PA-101 compared to patients treated with standard of care. The data were presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, LA.
-
Pharmaids Pharmaceuticals Announces FDA Clearance of IND Application for PA-101 for the Treatment of Acute Lymphoblastic Leukemia
Pharmaids Pharmaceuticals Ltd. (Nasdaq: PAHC), a clinical-stage biopharmaceutical company developing novel targeted therapies for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for PA-101 for the treatment of Acute Lymphoblastic Leukemia (ALL). This clearance allows the Company to initiate a Phase 2 clinical trial to evaluate the safety and efficacy of PA-101 in patients with relapsed or refractory ALL.
-
Pharmaids Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of PA-102 for the Treatment of Solid Tumors
Pharmaids Pharmaceuticals Ltd. (Nasdaq: PAHC), a clinical-stage biopharmaceutical company developing novel targeted therapies for the treatment of cancer, today announced the initiation of a Phase 2 clinical trial to evaluate the safety and efficacy of PA-102 for the treatment of solid tumors. PA-102 is a small molecule inhibitor of the WEE1 kinase, which is involved in the regulation of cell cycle.
-
Pharmaids Pharmaceuticals Ltd. Announces Positive Results from Phase 2 Clinical Trial of PPL-100
Pharmaids Pharmaceuticals Ltd. (NASDAQ: PHAR) today announced positive results from a Phase 2 clinical trial of PPL-100, its investigational drug for the treatment of moderate-to-severe psoriasis.
-
Pharmaids Pharmaceuticals Ltd. to Present at the 2023 American Academy of Dermatology Annual Meeting
Pharmaids Pharmaceuticals Ltd. (NASDAQ: PHAR) today announced that it will present data from its Phase 2 clinical trial of PPL-100, its investigational drug for the treatment of moderate-to-severe psoriasis, at the 2023 American Academy of Dermatology (AAD) Annual Meeting.
-
Pharmaids Pharmaceuticals Ltd. Announces FDA Clearance of IND Application for PPL-200
Pharmaids Pharmaceuticals Ltd. (NASDAQ: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PPL-200, its investigational drug for the treatment of moderate-to-severe atopic dermatitis.